In HCC models, REG in combination with immune checkpoint inhibitors was more effective at an intermittent dose, indicating that an optimal dose for immunomodulatory effects, which is different from the dose required for optimal single-agent antitumor activity, exists for REG [11, 17]. Here, REG1A is linked to hepatocellular carcinoma.